Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Abrocitinib by Pfizer for Dermatological Disorders: Likelihood of Approval
Abrocitinib is under clinical development by Pfizer and currently in Phase II for Dermatological Disorders. According to GlobalData, Phase II...
Abrocitinib by Pfizer for Prurigo: Likelihood of Approval
Abrocitinib is under clinical development by Pfizer and currently in Phase II for Prurigo. According to GlobalData, Phase II drugs...
Abrocitinib by Pfizer for Pruritus: Likelihood of Approval
Abrocitinib is under clinical development by Pfizer and currently in Phase II for Pruritus. According to GlobalData, Phase II drugs...